Association of adiponectin allele -11377 (C/G)polymorphism with type 2 diabetes and rosiglitazone response in Chinese patients

Abstract

Abstract: AIM: To evaluate the impact of adiponectin allele C-11377G genetic polymorphisms on efficacy of rosiglitazone in Chinese patients with type 2 diabetes (T2D).METHODS: Patients with T2D (n =255) and 120 heal thy volunteers were enrolled to identify-11377C/Ggenotypes by polymerase chain reaction restricti on fragment length polymorphism assay.Forty-two T2D patients with different-11377C/G genotypes received orally rosig litazone as asingle-dose therapy (4 mg day-1 p.o.) for 12 weeks.The serum triglyceride, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin(HbAlc), fasting serum insulin(FINS), postprandial serum insulin(PINS), total cholesterol(TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C), homeostasis model assessment for insulin resistance (HOMA-IR), and adiponectin concent ration were determined before and after rosiglitazonet reatment. RESULTS: Compared with the health control group, the allele frequency of-11377(C/G) and the genotypic frequency were increased in T2D group(P <0.05), and as the Gallele gene increased, the adiponectin level was significantly decreased, and the level s of FINS and HOMA-IR were significantly increased in T2D patient s(P < 0.05).After treated with rosiglitazone, the degree of the decrease of the FPG (P <0.01),PPG (P <0.05)and HOMA-IR (P<0.05)levels in the CC genotype was significanthigher than that in the othergenotypes.However, the degree of the increase of the serum adiponect in concentration(P<0.01)in the CC genotype was sig nificantly higher than that in the other genotypes.CONCLUSION: These data suggest that the adiponectin allele-11377C/G polymorphisms sig nificantly associated with the pathogenesis of T2D, insulin resistance, and the the rapeuticefficacy of rosiglitazone in Chinese patients with T2D.

Key words: Adiponectin, Genetic polymorphism, PCR-RFLP, Type 2 diabetes, Rosiglitazone

CLC Number:

R587.1

SUN Hong, WANG Shao-ming, ZHUANG Jie, LIU Hai-ling, ZHOU Hong-hao, LIU Zhao-qian. Association of adiponectin allele -11377 (C/G)polymorphism with type 2 diabetes and rosiglitazone response in Chinese patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 82-88.

References

[1] Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes[J]. J Bio l Chem, 1995, 270(45):26746-26749.
[2] Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients[J]. Arte rioscler Thromb Vasc Biol, 2000, 20(6):1595-1599.
[3] Mori Y, Otabe S, Dina C, et al. Genome-wide sear chfor type 2 diabete s in Japanese affected sibpairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p[J]. Diabetes, 2002, 51(4):1247-1255.
[4] Maeda N, Takahashi M, Funahashi T, et al. PPA R gammalig and sincrease expression and plasma concentrations of adiponectin and adipose derived protein[J]. Diabetes, 2001, 50(9):2094-2099.
[5] Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome prolife rator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients[J]. Diabetes Care, 2002, 25(2):376-380.
[6] Hotta K, Funahashi T, Bodkin NL, et al. Cir culating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkey s[J]. Diabetes, 2001, 50(5):1126-1133.
[7] Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus[J]. Diabetes Res Clin Pract, 2005, 67(1):43-52.
[8] Vasseur F, Helbeeque N, Dina C, et al. Single-nucleotide polymorphism haplotypes in the both proximal promoter and exon 3 of the APM1 gene modulate adipocy te-secre ted adiponec tin hormone levels and contribute to the gene tic risk for 2 diabete s in French Caucasians[J]. Hum Mol Gene t, 2002, 11(21):2607-2614.
[9] Populaire C, Mori Y, Dina C, et al. Does the -11377 promo tervariant of APM1 gene contribute to the genetic risk for Type 2 diabetes mellitus in Japanese families[J]. Diabe to logia, 2003, 46(3):443-445.
[10] Gu HF, Abulaiti A, Ostenson CG, et al. Sing le nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1)gene are associated with type 2 diabetes in Swedish Caucasians[J]. Diabetes, 2004, 53(Suppl):S31-S35.
[11] Schwarz PEH, Govindarajalu S, Tower s W, et al. Haplo types in the promo terregion of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population [J]. Horm Me tab Res, 2006, 38(7):447-451.
[12] Hara K, Boutin P, Moil Y, et al. Genetic variation in the gene encoding adiponec tin is associated with an increased risk of type 2 diabetes in the Japanese population[J]. Diabetes, 2002, 51(2):536-540.
[13] Menzaghi C, Ercolino T, Di Paola R, et al. Ahaplotype at the adiponectin locus is associa ted with obesity and other features of the insulin resistance syndrome[J]. Diabetes, 2002, 51(7):2306-2312.
[14] Yang WS, Tsou PL, Lee WJ, et al. Allele-specific differential expression of a common adiponectin gene polymorphism related to obesity[J]. J Mol Med, 2003, 81(7):428-434.
[15] 何岚, 刘萍, 叶枫, 等. 脂联素基因启动子区-11377C/G 单核苷酸多态性与陕西汉族人血清脂联素水平和2 型糖尿病的关系[J]. 第四军医大学报, 2006, 27(16):1493-1495.
[16] Populaire C, Mori Y, Dina C, et al. Does the -11377 promo tervariant of APM1 gene contribute to the genetic risk for Type 2 diabetes mellitus in Japanese families[J]. Diabe to logia, 2003, 46(3):443-445.
[17] Gu H F, Abulaiti A, Ostenson CG, et al. Single nucleotide polymorphisms in the proximal promoter region of the adiponectin (APM1)gene are associated with type 2 diabetes in Swedish Caucasians[J]. Diabetes, 2004, 53(Suppl):S31-S35.
[18] Kang ES, Park SY, Kim H J, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with ty pe 2 diabetes[J]. Diabetes Care, 2005, 28(5):1139-1144.